Trivastal Retard 50 Dosage/Direction for Use

Posology: Treatment of Parkinson's disease: as monotherapy: 150 mg to 250 mg, i.e. 3 to 5 tablets daily, to be divided into 3 to 5 administrations per day.
as a supplement to dopatherapy: 1 to 3 tablets daily (approximately 50 mg of piribedil per 250 mg of L.Dopa).
These doses must be attained gradually: increase by one tablet every three days.
Discontinuation of treatment: Sudden discontinuation of dopamine agents may result in neuroleptic malignant syndrome. To avoid this risk the dose of piribedil must be reduced gradually until complete discontinuation of treatment.
Impulse control disorders: To avoid the risk of impulse control disorders, prescription of the minimum effective dose is recommended. Dose reduction or gradual discontinuation of treatment should be considered if such symptoms occur (see Precautions).
Kidney or liver failure: Piribedil has not been studied in these groups of patients. It is recommended to treat these patients with caution.
Paediatric population: The safety and efficacy of piribedil in children under the age of 18 years have not been established. There is no available data. There is no justified use of piribedil in the paediatric population for this indication.
Method of administration: Oral route.
The tablets should be swallowed, without chewing, with half a glass of water at the end of the meal.